Rapid Treatment of Shock Without Trauma

Shock Clinical Trial

— SWOT  

Official title:

Implementation of a Mobile In-hospital Resuscitation Model for the Rapid Treatment of Shock Without Trauma (SWOT)

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT05073354
• Other study ID #: 50701
• Status: Enrolling by invitation
• Start date: June 29, 2021
• Est. completion date: May 29, 2024

Study information

• Verified date: July 2023
• Source: Zoll Medical Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Evaluate the implementation of a standardized mobile resuscitation model to manage SWOT within a large acute care hospital setting.

Description:

Immediately upon identification of SWOT, the SWOT Team will be activated by clinicians to respond to the patient bedside. Clinicians on-site will initiate patient care as directed by hospital protocol. Upon arrival, the SWOT Team will take over the management of patient care. The team will include 1-2 intensivists and multiple clinicians with clearly defined roles, dependent upon clinical presentation. The mobile resuscitative platform equipped with critical care technology will be delivered to the bedside (refer to appendix for full equipment content). The SWOT Team will implement goal-directed therapy using real-time monitoring and advanced diagnostic point-of-care tools. ultrasound, arterial and central lines will be placed by the intensivist(s) to monitor the physiology of the patient during treatment in real-time. Other team members (RNs, Respiratory Therapist's, residents, anesthesiologists, and technicians) will place the patient on continuous ECG and SPO2 monitoring, continuous capnographic monitoring via nasal canula or Endotracheal tube, and continuous cerebral and regional NIRS monitors. Point-of-care laboratory values will also be measured. Resuscitative interventions will be performed as directed by team leader to target the following physiological target parameters: - SpO2 > 85% - PaO2 > 50 mmHg - NIRS > 65% - Lactate normal or trending down - EtCO2 >20 mmHg - Mean Arterial Pressure > 65 mmHg - SVO2 > 60%

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 138
• Est. completion date: May 29, 2024
• Est. primary completion date: April 29, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. 18 to 75 years of age (inclusive)

2. Presence of shock, defined as systolic blood pressure (SBP) less than 90 mmHg with signs of hypoperfusion, including at least one of the following (without alternate

causes):

• low cardiac index (<2.2 L/min/m2)
• elevated filling pressures of the left heart (pulmonary capillary wedge pressure [PCWP] >15 mmHg) and/or
• right heart (central venous pressure [CVP] >10 mmHg)
• non-perfusing cardiac rhythm or cardiac arrest
• mixed venous oxygen saturation <60% or >80% without non-shock cause
• Heart rate >90 beats per minute
• Respiratory rate >20 breaths per minute
• White blood cell count >12 or < 4
• Temperature >38°C or <35°C
• SOFA score =2 with vasopressor requirement and elevated lactate >2 mmol/L (>18 mg/dL) despite adequate fluid resuscitation
• Central venous pressure <8 mmHg
• Obstruction such as pulmonary embolus on imaging

3. Admitted to Abbott Northwestern

4. Rapid Response Team call or request

5. Patients who previously agreed to allow their medical record information to be used for Allina Health research (i.e. Minnesota Research Authorization (MRA) "Yes") or those who have not explicitly declined use of their medical information in Allina Health research (i.e. MRA "Null")

Candidates for the prospective case series must meet the following inclusion criterion:

1. Interventional assessment and treatment by SWOT Team (full-implementation period only)

2. Patients who previously agreed to allow their medical record information to be used for Allina Health research (i.e. Minnesota Research Authorization (MRA) "Yes") or those who have not explicitly declined use of their medical information in Allina Health research (i.e. MRA "Null")

Exclusion Criteria:

1. Known or suspected pregnancy

2. Significant trauma

3. BMI > 50 kg/m2

4. Pre-existing Do Not Resuscitate order

5. Presence of orders limiting resuscitation efforts during the initial resuscitative period (less than 2 hours from the onset of protocol)

6. Refusal to receive whole blood or blood products

7. Severe brain injury (anoxic, traumatic, hemorrhagic or ischemic)

8. presence of an assist device such as intra-aortic balloon pump

9. Advanced chronic organ dysfunction

10. Known or presumed COVID-19

11. Patients with a status of MRA "No"

12. Patient in ICU at time of shock Candidates for the prospective case series will be excluded if the following condition is

present:

1. Patients with a status of MRA "No"

2. Patient in ICU at time of shock

Related Conditions & MeSH terms

• Shock

Intervention

Device:
• Full SWOT Model
Bundle of care that includes devices such as X Series monitor/defibrillator, AutoPusle automated compression device, Z Vent ventilator, and IPR therapies as well as bedside monitoring and diagnostics and training on a standardized care process.
• Partial SWOT Model
Historical control. Partial bundle of care that includes some bedside monitoring and diagnostics as well as training on a standardize care process

Other:
• Standard of Care
Standard of Care treatment to patients before development of SWOT protocol.

Locations

Country	Name	City	State
United States	Abbott Northwestern Hospital	Minneapolis	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Zoll Medical Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to Shock Reversal	Duration in minutes from activation of the SWOT Team to shock reversal, defined as stable arterial pressure (SBP > 90 mmHg) without requirement for vasopressor administration for greater than 24 hours and normalization of systemic and local perfusion measures of lab-measured lactate indicating improved systemic perfusion	From 24 hours to 72 hours after initial shock event
Secondary	30-day Mortality	Patient all-cause mortality will be assessed at 30 days following initial identification of shock symptoms	30 days after initial shock event